Arcturus Therapeutics Holdings宣布,已授予赛默飞世尔对其候选产品Arct-32的独家商业化生产权利。
此举旨在为Arct-32的未来全球供应建立稳固的制造基础,确保其商业化进程的可靠与高效。
Arcturus Therapeutics Holdings宣布,已授予赛默飞世尔对其候选产品Arct-32的独家商业化生产权利。
此举旨在为Arct-32的未来全球供应建立稳固的制造基础,确保其商业化进程的可靠与高效。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.